Drugs in upheaval: Rapid change in the way corporate America buys its healthcare is forcing pharmaceutical firms to rethink their marketing strategies

SMITHKLINE Beecham's surprise decision to splash out dollars 2.3bn ( pounds 1.5bn) last week on Diversified Pharmaceutical Services, one of the three biggest US pharmaceutical benefit managers, has presented arch- rival Glaxo with a tough choice.

Glaxo is under pressure to decide whether to run with the drug industry herd and risk losing a lot of money or to stand apart from the drug industry herd and risk losing a lot of money. Its instincts as a research-driven developer of prescription drugs lead it towards the second route. But the shifting balance of power within the US industry is driving it inexorably towards the first.

Like many of its rivals, the world's second largest drug company is faced with an immense challenge to its profits as the way in which corporate America buys its healthcare changes with frightening speed.

But as each of its competitors finds its own solution to that challenge, the options for Glaxo are narrowing.

The problem lies in the US, the world's biggest drug market. The past few years have seen a proliferation of pharmaceutical benefit managers - companies that manage the drug bills of employers who offer health insurance to their employees (see below).

PBMs, which already manage the drug needs of 50 million Americans, save their clients money by negotiating bulk discounts with drug companies and ensuring that patients use the cheapest possible product.

As such, they pose an enormous threat to drug company profits. They have acquired tremendous buying clout in a very short time. PBMs account for a quarter of all drugs sold in the US, a figure that could rise to 50 per cent within a few years.

Last November Merck, the world's largest drug company, decided that if it could not stop PBMs from eating into its margins it could at least buy a slice of their profits. It spent dollars 6.7bn on Medco, the biggest PBM and mail-order drug distributor, in a move that stunned the industry.

Analysts are divided on whether such vertical integration of manufacturer and distributor is the right way to go. It can easily fail - look at the fortunes lost by insurance companies and building societies when they bought up estate agencies, the high-street 'retail' end of their mortgage business.

Merck's move, however, upped the ante. Its rivals may have been undecided about the merits of vertical integration. But they were united in dreading a world in which buying decisions about their own products would ultimately be controlled by one of their rivals.

And they feared the competitive edge that Merck would gain by having access to the huge database of information about product effectiveness and cost provided by Medco.

The decision by SmithKline - the world's third-largest drug group - appears to put the seal on the agenda set by Merck. It has certainly put considerable pressure on Glaxo to act quickly if it is to follow suit. There are more than 100 PBMs in the US, but most are too small or regional to be of use to the big drug companies.

There are only half a dozen PBMs of any size; the biggest is Medco, now owned by Merck, while at least two others are spoken for - Diversified, which is being acquired by SmithKline, and Value Health, which has just signed a joint venture with US drug group Pfizer, which represents a halfway house to full integration.

That leaves one large PBM free: PCS, owned by McKesson Corp, America's biggest drug distributor. PCS is rumoured to be in talks with Glaxo; what is less clear is whether those talks involve an outright purchase or something more subtle.

With a pounds 2bn cash pile, Glaxo certainly could buy PCS - even though PBMs are growing so quickly that it would probably have to pay more than 50 times earnings to do so.

But Glaxo has been among the most sceptical of the outright purchase route. Its chief executive, Sir Richard Sykes, has argued coherently about the risks of vertical integration.

There is the concern that the loss of independence might undermine a PBM's client base, which could disappear in a very short space of time.

Why should clients trust a PBM owned by a drug company to offer them an objective service, after all? But if a drug company were to offer a completely objective PBM service, would that not defeat some of the purpose of buying it?

Then again, the trend in the healthcare management industry is towards 'capitation' - where the PBM offers to meet an employee's drug needs for a fixed cost per year. Such a path is fraught with danger, requiring the PBM to make actuarial- style judgements about the health of such employees.

All of which has so far led Glaxo to conclude that it is better off organising some form of alliance of drug companies, which would offer a range of complementary products to a PBM - and PCS might well be the most obvious choice.

An alliance of Glaxo's anti- ulcer products, with rival Wellcome's anti-virals, for instance, would be a powerful core to any theraputic menu - or 'formulary' as they are known.

This would give the drug- alliance companies access to the PBMs' databases, and also stop them from being squeezed out of the market altogether.

One such embryonic alliance - between Caremark International, a PBM, and drug groups Rhone-Poulenc Rorer, Bristol-Myers Squibb and Pfizer - has already been formed.

But alliances of drug groups are easier talked about than put together. If an alliance of companies offers a package of drugs - at a set price - to a PBM, then it must first decide how it shares out whatever profit is generated. And no drug group is likely to want to cede a better profit margin to any of its competitors than it receives itself.

Which is why Glaxo may prefer to buy a drug company with complementary products rather than form an alliance with its rivals. That was the logic behind last week's other big drug company acquisition: Roche, the Swiss drug manufacturer, bought Syntex, a US group, for dollars 5.3bn in a deal set to create the world's largest drug company.

Yet Glaxo is probably in a stronger position than any other company to tread a semi-independent path. It has some very promising new drugs with no obvious competitors - in particular its migraine drug. Where there are no competitors for a drug, a PBM is virtually forced to pay the price and include it on its formulary.

Glaxo also has a huge US sales force, which looks increasingly redundant. The sales people could be retrained to market a range of drugs at PBMs - Glaxo was, after all, one of the first companies to have staff dedicated to selling to PBMs.

Or the same employees could provide healthcare education to the members of healthcare plans.

But while Glaxo has not yet run out of options, it is beginning to run out of time.

(Photograph omitted)

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
News
Starting the day with a three-egg omelette could make people more charitable, according to new research
science
News
Top Gun actor Val Kilmer lost his small claims court battle in Van Nuys with the landlord of his Malibu mansion to get back his deposit after wallpapering over the kitchen cabinets
people
News
Comedian Ted Robbins collapsed on stage during a performance of Phoenix Nights Live at Manchester Arena (Rex)
people
News
The actress Geraldine McEwan was perhaps best known for playing Agatha Christie's detective, Miss Marple (Rex)
peopleShe won a Bafta in 1991 for her role in Oranges Are Not The Only Fruit
News
newsPatrick Cockburn was able to update his agenda-setting 'The Rise of Islamic State' while under attack in Baghdad
News
Robert Fraser, aka Groovy Bob
peopleA new show honours Robert Fraser, one of the era's forgotten players
Life and Style
Torsten Sherwood's Noook is a simple construction toy for creating mini-architecture
tech
Sport
David Silva celebrates with Sergio Aguero after equalising against Chelsea
footballChelsea 1 Manchester City 1
ebooks
ebooksA special investigation by Andy McSmith
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Software Development Manager

£40000 - £50000 per annum: Recruitment Genius: This is an exciting opportunity...

Ashdown Group: Product Manager - (Product Marketing, Financial Services)

£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...

Recruitment Genius: Compliance Assistant

£13000 per annum: Recruitment Genius: This Pension Specialist was established ...

Ashdown Group: Market Research Executive

£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...

Day In a Page

As in 1942, Germany must show restraint over Greece

As in 1942, Germany must show restraint over Greece

Mussolini tried to warn his ally of the danger of bringing the country to its knees. So should we, says Patrick Cockburn
Britain's widening poverty gap should be causing outrage at the start of the election campaign

The short stroll that should be our walk of shame

Courting the global elite has failed to benefit Britain, as the vast disparity in wealth on display in the capital shows
Homeless Veterans appeal: The rise of the working poor: when having a job cannot prevent poverty

Homeless Veterans appeal

The rise of the working poor: when having a job cannot prevent poverty
Prince Charles the saviour of the nation? A new book highlights concerns about how political he will be when he eventually becomes king

Prince Charles the saviour of the nation?

A new book highlights concerns about how political he will be when he eventually becomes king
How books can defeat Isis: Patrick Cockburn was able to update his agenda-setting 'The Rise of Islamic State' while under attack in Baghdad

How books can defeat Isis

Patrick Cockburn was able to update his agenda-setting 'The Rise of Islamic State' while under attack in Baghdad
Judith Hackitt: The myths of elf 'n' safety

Judith Hackitt: The myths of elf 'n' safety

She may be in charge of minimising our risks of injury, but the chair of the Health and Safety Executive still wants children to be able to hurt themselves
The open loathing between Barack Obama and Benjamin Netanyahu just got worse

The open loathing between Obama and Netanyahu just got worse

The Israeli PM's relationship with the Obama has always been chilly, but going over the President's head on Iran will do him no favours, says Rupert Cornwell
French chefs get 'le huff' as nation slips down global cuisine rankings

French chefs get 'le huff' as nation slips down global cuisine rankings

Fury at British best restaurants survey sees French magazine produce a rival list
Star choreographer Matthew Bourne gives young carers a chance to perform at Sadler's Wells

Young carers to make dance debut

What happened when superstar choreographer Matthew Bourne encouraged 27 teenage carers to think about themselves for once?
Design Council's 70th anniversary: Four of the most intriguing prototypes from Ones to Watch

Design Council's 70th anniversary

Four of the most intriguing prototypes from Ones to Watch
Dame Harriet Walter: The actress on learning what it is to age, plastic surgery, and her unease at being honoured by the establishment

Dame Harriet Walter interview

The actress on learning what it is to age, plastic surgery, and her unease at being honoured by the establishment
Art should not be a slave to the ideas driving it

Art should not be a slave to the ideas driving it

Critics of Tom Stoppard's new play seem to agree that cerebral can never trump character, says DJ Taylor
Bill Granger recipes: Our chef's winter salads will make you feel energised through February

Bill Granger's winter salads

Salads aren't just a bit on the side, says our chef - their crunch, colour and natural goodness are perfect for a midwinter pick-me-up
England vs Wales: Cool head George Ford ready to put out dragon fire

George Ford: Cool head ready to put out dragon fire

No 10’s calmness under pressure will be key for England in Cardiff
Michael Calvin: Time for Old Firm to put aside bigotry and forge new links

Michael Calvin's Last Word

Time for Old Firm to put aside bigotry and forge new links